In Brief: St. Jude
This article was originally published in The Gray Sheet
Executive Summary
St. Jude: St. Paul, Minnesota-based firm organizing tachycardia personnel and resources under the leadership of Mark Kroll, PhD, former VP Research and Product Planning at Minneapolis-based Angeion Corporation, who is appointed VP of the new St. Jude tachycardia division. St. Jude plans to form an advanced tachycardia research team in Minnesota to further its platform tachycardia technology; the firm holds rights to the technology through ongoing cross-patent and technology licensing agreements with Angeion. The firm also holds a worldwide distribution agreement to sell Angeion's Sentinel 2000 and 2001 implantable cardiac defibrillator models under a Pacesetter tradename. St. Jude expects the first implant of the ICD to occur in early 1996, according to an Oct. 31 release. In a separate release, Angeion reports that it received FDA approval to begin its own clinical trials in the U.S. for the Sentinel 2000 defibrillation system...
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.